Parameter
| Biomarker | IL-1β | Full name | Interleukin-1β | Molecular Type | Cytokine |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prognosis |
| Disease | Epilepsy | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Serum/Cerebrospinal Fluid (ELISA, qPCR) | ||
| Pathobiological Mechanisms | Activates the NF-κB/MAPK pathway, enhances glutamate release in the hippocampus, inhibits GABAₐ receptor function, and exacerbates neuronal hyperexcitability. | ||||
| Clinical Availability Status | Under clinical validation | ||||
| Notes and Dynamics | CSF IL-1β levels in refractory TLE patients are 2.1 times higher than those in drug-sensitive patients; the caspase-1 inhibitor VX-765 can reduce seizure frequency. | ||||